InMode builds radio-frequency platforms for minimally invasive and surgical procedures across plastic surgery, gynecology, dermatology, ENT, and ophthalmology.
InMode's expanding consumables and service revenue provides a foundation for resilience, on the condition that this stream keeps growing. Full-year revenues from consumables and service reached $81.4 million, a 3% increase compared with 2024. The fall in total revenue is the primary risk to that condition.
InMode's total revenues for 2025 were $370.5 million, a decrease of 6% compared with 2024.
2Risk Factors
Serious reported complications make safe use and provider training material conditions for radiofrequency microneedling demand, and the reported adverse events are not connected to InMode devices specifically. The U.S. Food and Drug Administration warned consumers, patients, and health care providers about potential serious complications from radiofrequency microneedling procedures.
Specific reported harms include severe burns, permanent scarring, fat loss, physical disfigurement, and nerve damage.